Skip to main content

Table 2 Summary of Effectiveness

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

Ā 

GEM-E

GEM

p-valuea

(nā€‰=ā€‰1,331)

(nā€‰=ā€‰2,936)

Ā 

Overall survival time, months

ā€ƒMeanā€‰Ā±ā€‰SD

10.48

9.86

0.0977

(325.5 daysā€‰Ā±ā€‰8.9)

(305.6 daysā€‰Ā±ā€‰5.4)

ā€ƒMedian

6.77

6.68

Ā 

(210 days)

(207 days)

Overall survival rate per treatment time, %

ā€ƒ6 months

56.5

54.7

0.2108

ā€ƒ12 months

27.0

27.3

0.5988

ā€ƒ24 months

12.9

10.6

0.1350

ā€ƒ36 months

9.3

6.5

0.0977

  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabineā€‰+ā€‰Erlotinib
  2. alog-rank test